Published: Dec 18, 2020
BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that its Investigational New Drug (IND) application for CAN106, a recombinant human monoclonal antibody targeting complement C5 of the complement system, has been approved by the Health Sciences Authority (HSA) in Singapore for the treatment of complement dysregulation diseases. The first indication is paroxysmal nocturnal hemoglobinuria (PNH), a fatal disease in which the complement system destroys red blood cells.
CAN106 is being developed for multiple diseases associated with complement dysregulation. The complement system is the part of the immune system that helps antibodies and phagocytic cells clear microbes and damaged cells. Dysregulation of the proteins that compose it leads to several rare diseases, including PNH. CANbridge holds the proprietary global righ